Year None2022202120202019201820172016201520142013 Jul 1 View HTML version View PDF Version Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab) Jun 29 View HTML version View PDF Version EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review Jun 24 View HTML version View PDF Version Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose Jun 7 View HTML version View PDF Version FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Jun 2 View HTML version View PDF Version Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer May 31 View HTML version View PDF Version Regeneron Completes Acquisition of Checkmate Pharmaceuticals May 31 View HTML version View PDF Version FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis May 21 View HTML version View PDF Version Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol May 20 View HTML version View PDF Version FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis May 13 View HTML version View PDF Version High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair Current page 1 Page 2 Page 3 Page 4 Next page › Last page »